论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Chen S, Na N, Jian Z
Received 29 July 2017
Accepted for publication 27 October 2017
Published 21 December 2017 Volume 2018:11 Pages 59—65
DOI https://doi.org/10.2147/OTT.S147715
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Ingrid Espinoza
Background: The relationship
between platelet counts and pancreatic cancer as a prognostic factor has been
reported in many studies. We aimed to evaluate the prognostic value of platelet
counts in predicting the prognosis of pancreatic cancer patients.
Methods: We searched PubMed, Medline, EMBASE, and Google
Scholar for eligible studies up to May 2017. Information about the
characteristics of the study and relevant outcomes was extracted. A
meta-analysis was performed to analyze the prognostic value of platelet counts
using the hazard ratio (HR) and 95% confidence intervals (CIs).
Results: A total of 1,756 patients in 13 retrospective
studies were included. The pooled HR of 1.51 (95% CI: 1.20–1.90, P <0.001) showed that patients
with elevated platelet counts were expected to have poor overall survival after
treatment. Subgroup analysis showed that prognostic value of platelet levels
was stronger in patients who received surgical resection (HR =1.60, 95% CI:
1.09–2.34, P =0.02), followed by patients who
received palliative therapy (HR =1.46, 95% CI: 1.03–2.06, P =0.03).
Conclusion: Platelet counts could be a useful prognostic
marker for pancreatic cancer. Patients with high platelet counts are expected
to have poor survival.
Keywords: pancreatic
adenocarcinoma, blood parameters, platelet, prognosis, evidence-based medicine